Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...

Layoffs, funding freezes, and executive orders spark outcry among federal researchers and university partners, fearing that ...

Company shares preliminary results from Phase 1/2 clinical trial for patients with advanced Retinitis Pigmentosa (RP) NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bionic Sight, Inc., a company ...

Grant funding uncertainty has jeopardized the sustainability of research projects and discouraged researchers.

The first of Opthea’s (ASX:OPT) two phase III eye disease trials has hit a key development milestone, with the last patient ...

IQVIA has seen an increase of 58.97% in its revenues since 2017. Click here to read more about IQV stock and why it is rated ...

The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...